1-2 of 2
Jose Ballester-Beltrán
Close
Sort by
Journal Articles

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Georgina S.F. Anderson, Jose Ballester-Beltran, George Giotopoulos, Jose A. Guerrero, Sylvanie Surget, James C. Williamson, Tsz So, David Bloxham, Anna Aubareda, Ryan Asby, Ieuan Walker, Lesley Jenkinson, Elizabeth J. Soilleux, James P. Roy, Ana Teodósio, Catherine Ficken, Leah Officer-Jones, Sara Nasser, Sheri Skerget, Jonathan J. Keats, Peter Greaves, Yu-Tzu Tai, Kenneth C. Anderson, Marion MacFarlane, James E. Thaventhiran, Brian J.P. Huntly, Paul J. Lehner, Michael A. Chapman
Journal: Blood
Blood (2022) 139 (16): 2471–2482.
https://doi.org/10.1182/blood.2021015161
Published: 2022
Includes: Supplemental data
Journal Articles

CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia

Cavan Bennett, Moyra Lawrence, Jose A. Guerrero, Simon Stritt, Amie K. Waller, Yahui Yan, Richard W. Mifsud, Jose Ballester-Beltrán, Ayesha Baig, Annett Mueller, Louisa Mayer, James Warland, Christopher J. Penkett, Parsa Akbari, Thomas Moreau, Amanda L. Evans, Souradip Mookerjee, Gary J. Hoffman, Kourosh Saeb-Parsy, David J. Adams, Amber L. Couzens, Markus Bender, Wendy N. Erber, Bernhard Nieswandt, Randy J. Read, Cedric Ghevaert
Journal: Blood
Blood (2022) 139 (14): 2227–2239.
https://doi.org/10.1182/blood.2021013113
Published: 2022
Includes: Multimedia, Supplemental data